Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3569836 | 0.77 | — | — | |
| SCHEMBL7521564 | 0.77 | FFAR3 (0.38) | CA1CA2ALOX15ALDH1A1 | |
| SCHEMBL28171019 | 0.76 | CA1 (0.34) | CA1CA2ALOX15KDM4EALDH1A1 | |
| SCHEMBL27142712 | 0.76 | LMNA (0.39) | — | |
| SCHEMBL3581688 | 0.75 | — | — | |
| SCHEMBL11284503 | 0.74 | — | — | |
| SCHEMBL4652322 | 0.74 | — | — | |
| SCHEMBL29846315 | 0.73 | TSHR (0.42) | CA2ALDH1A1 | |
| SCHEMBL29847028 | 0.71 | GAA (0.48) | CA1CA2ALOX15ALDH1A1 | |
| SCHEMBL11281641 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729269-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2014-05-20 | — | — | US | disclosed |
| US-20100144735-A1 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | WOCKHARDT LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-7687627-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2010-03-30 | — | — | US | disclosed |
| EP-1664038-A2 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED I IN VIVO /I EFFICACY | Wockhardt Limited (IN) | 2006-06-07 | — | — | EP | disclosed |
| US-20050143421-A1 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED | 2005-06-30 | — | — | US | disclosed |
| WO-2005054234-A2 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | WOCKHARDT LIMITED (IN) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144735-A1 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | GMPS, MPO, ARG1 | CA1 4872/4885CA2 4814/4885ALOX15 1405/4885 |
| US-20050143421-A1 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | GMPS, MPO, ARG1 | CA1 4872/4885CA2 4814/4885ALOX15 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.